Sage Therapeutics Inc - Asset Resilience Ratio
Sage Therapeutics Inc (SAGE) has an Asset Resilience Ratio of 70.48% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Sage Therapeutics Inc's working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Sage Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Sage Therapeutics Inc's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down Sage Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read SAGE total debt and obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $298.08 Million | 70.48% |
| Total Liquid Assets | $298.08 Million | 70.48% |
Asset Resilience Insights
- Very High Liquidity: Sage Therapeutics Inc maintains exceptional liquid asset reserves at 70.48% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Sage Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Sage Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Sage Therapeutics Inc (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Sage Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 77.37% | $423.40 Million | $547.22 Million | +0.05pp |
| 2023-12-31 | 77.32% | $682.19 Million | $882.28 Million | -4.49pp |
| 2022-12-31 | 81.82% | $1.11 Billion | $1.36 Billion | +2.48pp |
| 2021-12-31 | 79.33% | $1.45 Billion | $1.83 Billion | +59.03pp |
| 2020-12-31 | 20.31% | $438.47 Million | $2.16 Billion | -61.02pp |
| 2019-12-31 | 81.33% | $881.69 Million | $1.08 Billion | +4.51pp |
| 2018-12-31 | 76.82% | $731.83 Million | $952.71 Million | +36.70pp |
| 2017-12-31 | 40.12% | $212.61 Million | $529.94 Million | -16.48pp |
| 2016-12-31 | 56.60% | $228.96 Million | $404.53 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $189.02 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $129.66 Million | -- |
About Sage Therapeutics Inc
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults. Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric m… Read more